-$0.34 EPS Expected for Jounce Therapeutics Inc (JNCE) This Quarter
Equities analysts forecast that Jounce Therapeutics Inc (NASDAQ:JNCE) will announce earnings per share of ($0.34) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Jounce Therapeutics’ earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.42). Jounce Therapeutics posted earnings of ($0.13) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 161.5%. The business is expected to announce its next quarterly earnings report on Monday, November 12th.
On average, analysts expect that Jounce Therapeutics will report full year earnings of ($1.26) per share for the current fiscal year, with EPS estimates ranging from ($1.44) to ($1.08). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.22) per share, with EPS estimates ranging from ($2.33) to ($0.25). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings data on Friday, August 10th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.23. The firm had revenue of $19.38 million for the quarter, compared to analysts’ expectations of $12.47 million. Jounce Therapeutics had a negative return on equity of 23.27% and a negative net margin of 50.54%.
Several hedge funds and other institutional investors have recently modified their holdings of JNCE. venBio Select Advisor LLC bought a new position in shares of Jounce Therapeutics in the first quarter worth $11,693,000. Millennium Management LLC grew its position in Jounce Therapeutics by 91.6% in the second quarter. Millennium Management LLC now owns 679,177 shares of the company’s stock valued at $5,202,000 after acquiring an additional 324,681 shares during the last quarter. Citadel Advisors LLC bought a new position in Jounce Therapeutics in the first quarter valued at about $6,539,000. BlackRock Inc. grew its position in Jounce Therapeutics by 22.2% in the second quarter. BlackRock Inc. now owns 1,394,905 shares of the company’s stock valued at $10,684,000 after acquiring an additional 253,120 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Jounce Therapeutics by 186.0% in the second quarter. Dimensional Fund Advisors LP now owns 314,831 shares of the company’s stock valued at $2,412,000 after acquiring an additional 204,762 shares during the last quarter. Institutional investors own 84.11% of the company’s stock.
JNCE stock traded down $0.03 during trading hours on Monday, hitting $7.19. 11,346 shares of the stock were exchanged, compared to its average volume of 265,303. The stock has a market capitalization of $235.57 million, a price-to-earnings ratio of -12.61 and a beta of 5.23. Jounce Therapeutics has a 12 month low of $6.56 and a 12 month high of $29.25.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
Read More: How to Invest in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.